Conference Dates
June 12 – 17, 2022
Abstract
Human Endogenous Retroviruses (HERVs) are promising cancer vaccine targets as they are reactivated in cancers while being silent in healthy tissues. Around 8-9% of our genome is made up of HERVs and reactivation of HERVs, especially HERV-K, have been implicated in tumorigenesis via oncogenic signaling and immune evasion. As one of the means for cancer immune evasion, HERVs utilize an Immune Suppressive Domain (ISD) located in their envelope protein (Env). Here, our cancer vaccine strategy was to evaluate if adenoviral vaccines encoding a virus-like particle immunogen design including Gag for particle formation and an ISD mutated Env protein (ISDmut) as a surface target, could induce potent and efficacious immune responses. For this purpose, we used the adenoviral vectors hAd19a and hAd5.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Anne-Marie Andersson, Emeline Ragonnaud, Joana D. Boluña, Isabella S. Pedersen, Amaia V. Bermejo, Lasse Neukirch, Karen N. Nielsen, Silke Schroedel, Christian Thirion, and Peter J. Holst, "Targeting endogenous retroviruses using a novel adenoviral vaccine technology" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/8